Calidi Biotherapeutics マネジメント

マネジメント基準チェック /44

Calidi Biotherapeuticsの CEO はAllan Camaisaで、 Feb2018年に任命され、の在任期間は 6.75年です。の年間総報酬は$ 436.51Kで、 58.9%給与と41.1%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.4%を直接所有しており、その価値は$ 148.05K 。経営陣と取締役会の平均在任期間はそれぞれ6.8年と3.8年です。

主要情報

Allan Camaisa

最高経営責任者

US$436.5k

報酬総額

CEO給与比率	58.9%
CEO在任期間	6.8yrs
CEOの所有権	0.4%
経営陣の平均在職期間	6.8yrs
取締役会の平均在任期間	3.8yrs

経営陣の近況

Recent updates

CEO報酬分析

Calidi Biotherapeutics の収益と比較して、Allan Camaisa の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2024	n/a	n/a	-US$28m
Jun 30 2024	n/a	n/a	-US$25m
Mar 31 2024	n/a	n/a	-US$30m
Dec 31 2023	US$437k	US$257k	-US$29m
Sep 30 2023	n/a	n/a	-US$29m
Jun 30 2023	n/a	n/a	-US$32m
Mar 31 2023	n/a	n/a	-US$24m
Dec 31 2022	US$2m	US$43k	-US$25m
Sep 30 2022	n/a	n/a	-US$21m
Dec 31 2021	US$1m	US$26k	-US$11m

報酬と市場: Allanの総報酬 ($USD 436.51K ) は、 US市場 ($USD 647.72K ) の同様の規模の企業の平均を下回っています。

報酬と収益: Allanの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Allan Camaisa (64 yo)

6.8yrs

在職期間

US$436,512

報酬

Mr. Allan J. Camaisa serves as Chief Executive Officer and Chairman of the Board at Calidi Biotherapeutics, Inc since February 2018. He served as Chief Executive Officer and Chairman at Parallel 6, Inc. si...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Allan Camaisa	CEO & Chairman of the Board	6.8yrs	US$436.51k	0.40% $ 148.1k
Wendy Pizarro Campbell	Chief Administrative Officer	3.2yrs	US$295.40k	0.084% $ 31.3k
Boris Minev	President of Medical & Scientific Affairs and Interim Chief Medical Officer	9.4yrs	US$400.10k	0.22% $ 81.9k
Andrew Jackson	Chief Financial Officer	1.1yrs	データなし	データなし
Stephen Thesing	Chief Business Officer	8.8yrs	データなし	0.24% $ 91.0k

6.8yrs

平均在職期間

58yo

平均年齢

経験豊富な経営陣: CLDIの経営陣は経験豊富で経験豊富です（平均在職期間は6.8年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Allan Camaisa	CEO & Chairman of the Board	6.8yrs	US$436.51k	0.40% $ 148.1k
James Schoeneck	Independent Director	4.3yrs	US$109.56k	0.53% $ 197.4k
W.K. Yung	Member of Medical Advisory Board	2.4yrs	データなし	データなし
Ewa Carrier	Member of Medical Advisory Board	no data	データなし	データなし
George Peoples	Independent Director	less than a year	データなし	0.00089% $ 331.8
Scott Leftwich	Independent Vice-Chairman of the Board	5.5yrs	US$179.89k	1.23% $ 459.1k
Alan Stewart	Independent Director	1.1yrs	US$120.56k	0.029% $ 10.7k
Santosh Kesari	Member of Medical Advisory Board	no data	データなし	データなし
Dmitriy Zamarin	Member of Scientific Advisory Board	3.8yrs	データなし	データなし
Ashok Srivastava	Member of Scientific Advisory Board	no data	データなし	データなし
Karen Aboody	Member of Medical Advisory Board	no data	データなし	データなし
Maciej Lesniak	Member of Medical Advisory Board	no data	データなし	データなし

3.8yrs

平均在職期間

63.5yo

平均年齢

経験豊富なボード: CLDIの取締役会は経験豊富であると考えられます ( 3.8年の平均在任期間)。

Calidi Biotherapeutics マネジメント

マネジメント 基準チェック /44

主要情報

経営陣の近況

Calidi Biotherapeutics, Inc., Annual General Meeting, Sep 20, 2024

Calidi Biotherapeutics, Inc. Announces George Ng Decision to Allow the Term of His Position as a Director of the Board to Expire and to Not Seek Re-Election to the Board

Calidi Biotherapeutics, Inc. Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board

Calidi Biotherapeutics, Inc. Appoints George E. Peoples to Its Board of Directors

Independent Director exercised options to buy US$106k worth of stock.

Calidi Biotherapeutics, Inc. Announces Scientific and Medical Advisory Board Appointments

Recent updates

Calidi Biotherapeutics Inc. Presents Data Supporting RTNova Systemic Technology to Target Metastatic Lung Cancer

Calidi Biotherapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $7.499999 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering.

Calidi Biotherapeutics Inc. to Present Data Supporting RTNova at Upcoming Scientific Conferences

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.05 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.05 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $2.05 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.1 million.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $5.1 million.

Calidi Biotherapeutics, Inc. Announces FDA Clearance of the Northwestern University IND Application for CLD-101 Clinical Trial in High-Grade Glioma

Calidi Biotherapeutics, Inc., Annual General Meeting, Sep 20, 2024

Calidi Biotherapeutics, Inc. Announces George Ng Decision to Allow the Term of His Position as a Director of the Board to Expire and to Not Seek Re-Election to the Board

Calidi Biotherapeutics, Inc. Announces Appointment of Dr. Mark Gilbert to Medical Advisory Board

Calidi Biotherapeutics, Inc. Appoints George E. Peoples to Its Board of Directors

Independent Director exercised options to buy US$106k worth of stock.

Calidi Biotherapeutics Presents Cld-101 Phase 1 Trial Update and Preclinical Data Highlighting Rtnova and Cld-201 At 2024 Asco Annual Meeting

New major risk - Financial position

New major risk - Market cap size

New major risk - Revenue and earnings growth

Calidi Biotherapeutics, Inc. announced that it has received $3.5 million in funding

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering.

Calidi Biotherapeutics, Inc. has filed a Follow-on Equity Offering.

Calidi Biotherapeutics, Inc. Announces Scientific and Medical Advisory Board Appointments

Less than half of directors are independent

Calidi Biotherapeutics Announces Directorate Changes

Calidi Biotherapeutics, Inc. Announces the Resignation of Alfonso Zulueta as A Director, Including His Position on Audit Committee of the Board

New major risk - Financial position

New major risk - Shareholder dilution

Calidi Biotherapeutics, Inc. Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer's 38th Annual Meeting

Calidi Biotherapeutics, Inc. Presents Data on CLD-201 Demonstrating Inhibition of Tumor Growth and Induction of Robust Anti-Tumor Immunity at the Society for Immunotherapy of Cancer's 38th Annual Meeting

Calidi Biotherapeutics, Inc. Announces Key Leadership Promotions and New Board Appointment

Calidi Biotherapeutics, Inc. Enters into an Employment Agreement with Andrew Jackson to Serve as Chief Financial Officer

Calidi Biotherapeutics, Inc. Announces Resignation of Tony Kalajian as Interim Chief Financial Officer

Calidi Biotherapeutics, Inc. Announces Resignation of Tony Kalajian as Chief Accounting Officer

Less than half of directors are independent

Calidi Biotherapeutics, Inc. Appoints Alan R. Stewart as the Class I Director

Calidi Biotherapeutics, Inc. Announces the Resignation of Dr. Heehyoung Lee, Including All Her Positions on the Committees of the Board

Calidi Biotherapeutics, Inc. Announces the Resignation of Dr. Heehyoung Lee, Including All Her Positions on the Committees of the Board

Calidi Biotherapeutics, Inc. announced that it has received funding from Jackson Investment Group, Calidi Cure, LLC

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

平均年齢

取締役

平均在職期間

平均年齢

マネジメント基準チェック /44